Back to rankings

Colgate-Palmolive Co (CL)

Overvalued
Consumer DefensiveHousehold & Personal ProductsUnited States

Fundamental

55

Price

$94.04

Market Cap

$74.46B

Part 1 · What the company is worth

Overview

Colgate-Palmolive is a global consumer products company founded in 1806 that manufactures and markets a portfolio of oral care, personal care, home care, and pet nutrition products. The company holds market-leading positions in toothpaste, manual toothbrushes, and hand soaps, and operates a specialty pet nutrition business (Hill's Science Diet and Hill's Prescription Diet) across more than 200 countries and territories. Approximately two-thirds of net sales originate outside the United States.

How it makes money

The company generates revenue through direct sales to retailers, wholesalers, and distributors worldwide; direct-to-consumer e-commerce channels; veterinary and specialized retailers for pet nutrition products; and wholesale arrangements with authorized retailers. Revenue is supported by substantial advertising, promotion, and marketing investments to maintain brand awareness and pricing power.

Revenue by segment

Oral Care43%

Toothpaste, manual and electric toothbrushes, dental floss, mouthwash, and other oral hygiene products sold globally under the Colgate, elmex, meridol, and Darlie brands. This is the company's largest and most profitable segment with global market leadership.

Pet Nutrition22%

Specialty pet nutrition products for dogs and cats sold under the Hill's Science Diet and Hill's Prescription Diet brands through veterinarians, authorized pet specialty retailers, and e-commerce channels in over 80 countries. Includes both therapeutic and wellness-focused formulations.

Personal Care18%

Liquid hand soaps, body washes, bar soaps, deodorants, and personal cleansing products marketed under brands including Palmolive, Sanex, Irish Spring, and Tom's of Maine. Products target daily hygiene and wellness.

Home Care17%

Laundry detergents, fabric conditioners, dish soaps, and household cleaning products. These products are primarily sold in select markets and represent an important part of the personal and home care category.

Competitive moat

Brand · Narrow

Colgate holds strong brand recognition and market leadership in oral care globally, particularly in toothpaste and manual toothbrushes, supported by a century-old trademark portfolio and significant distribution infrastructure. However, the moat is narrowed by intense global competition from multinational competitors, strong private-label offerings, and increasing e-commerce channels that reduce barriers to entry. In pet nutrition, Hill's has established reputation but competes against well-funded rivals. The company's ability to sustain pricing power is constrained by consumer price sensitivity and retail consolidation.

What drives demand

Defensive

Oral care and personal care products are non-discretionary consumer staples that remain in demand across economic cycles. Consumers continue to purchase toothpaste, hand soap, and household cleaning products regardless of economic downturns. However, demand can shift toward lower-priced private-label alternatives during recessions or periods of consumer cost-consciousness. Pet nutrition demand has moderate cyclicality, as pet owners may trade down to economy pet food during economic stress, though premium pet wellness products have shown resilience as consumers view pets as family members and prioritize their health.

Key risks

  • Foreign Exchange Exposure — Approximately two-thirds of net sales originate from markets outside the United States, exposing the company to significant foreign exchange headwinds. Currency devaluation in key markets can reduce reported earnings and competitiveness against local rivals. Macroeconomic volatility and trade policy changes add complexity to hedging strategies.
  • Intense Global Competition — The company faces vigorous competition from strong local competitors, multinational firms with greater resources, and new e-commerce entrants that have reduced barriers to market entry. Competitors may spend more on advertising, introduce differentiated products faster, or respond more effectively to changing business and economic conditions. Private-label alternatives pose a particular threat during periods of consumer price sensitivity.
  • Retail Consolidation and Customer Concentration — Walmart and affiliates represented approximately 11% of 2024 net sales, and no other single customer exceeded 10%. The increasing consolidation of retail channels reduces the company's bargaining power and exposes it to concentration risk. Loss of a major retailer or significant reduction in orders could materially impact sales and profitability.
  • Supply Chain Disruption Risk — Significant disruptions to manufacturing or sourcing of products or materials could interrupt product supply and harm the business. The company relies on single-source suppliers for certain materials and faces geopolitical risks from ongoing conflicts including the Ukraine war. Logistics constraints and pandemic-related scenarios continue to pose operational threats.
  • Commodity Cost Volatility — Raw and packaging material commodities are subject to market price variations. Increases in costs of commodities, energy, and labor have adversely affected profit margins historically and are likely to continue doing so. The company's ability to offset these increases through pricing is limited by consumer price sensitivity and competitive pressures.
  • Brand and Reputation Risk — Maintaining strong consumer reputation is critical to selling branded products. Negative publicity about the company, its brands, or its products—whether deserved or not—could jeopardize reputation and sales. The company also faces risks from counterfeit products that may pose safety risks to consumers and undermine brand equity.
  • Regulatory and Intellectual Property Risk — Products are subject to extensive governmental regulations including FDA, FTC, EPA, and international regulatory oversight. If the company is found to have infringed trademark, patent, or other intellectual property rights, it could adversely affect its ability to develop and commercialize innovative products. The company is also subject to anti-corruption laws and regulations including the Foreign Corrupt Practices Act.

Customer concentration

Top customers account for 11% of revenue

Walmart and its affiliates represented approximately 11% of 2024 net sales, making it the company's largest single customer. No other customer accounted for more than 10% of net sales. While this concentration is relatively moderate compared to peers, the dependence on large retailers is a strategic risk, as consolidation in retail channels continues to increase the bargaining power of major chains.

The case for

Buyers argue that Colgate-Palmolive is a defensive, cash-generative consumer staples business with iconic, century-old global brands and market-leading positions in oral care. The company has successfully navigated multiple economic cycles by maintaining pricing power through brand strength while expanding into higher-margin specialty categories like premium pet nutrition (Hill's) and therapeutic oral care products. Growth opportunities exist in emerging markets where oral care penetration remains low, and the company's recent shift toward e-commerce and direct-to-consumer channels provides improved margins and customer data. The combination of a stable defensive business, global diversification, and shareholder-friendly dividend policies makes the stock attractive for income-oriented investors seeking reliable returns with moderate inflation protection.

The case against

Sellers fear that Colgate-Palmolive faces structural headwinds from intensifying global competition, the rise of private-label alternatives, and e-commerce disruption that has eroded traditional pricing power. The company's consumer price increases have faced resistance, with data suggesting consumers are switching to lower-priced alternatives or reducing volume, indicating that pricing power may be waning. Geopolitical uncertainty and the company's significant international exposure (two-thirds of sales) create vulnerability to currency devaluation and trade disruptions. Pet Nutrition, while growing, remains cyclical and subject to trading-down during economic downturns. The company's heavy dependence on retail consolidation exposes it to customer concentration risk with Walmart representing 11% of sales. Rising commodity and labor costs, combined with limited ability to pass through increases to consumers, will likely pressure margins going forward. Finally, as a mature, slow-growth business, the company offers limited upside for growth investors and is vulnerable to valuation compression in higher interest rate environments.

Generated with artificial intelligence on September 21, 2026, shared with all users

Direct competitors

Who this company fights with for the same customers

Compare

Generated with artificial intelligence on September 18, 2026, shared with all users

P/E: 24.3Score: 61Market cap: $364.56B

P&G sells to the same supermarket shoppers in nearly every Colgate category, with Crest and Oral-B against Colgate toothpaste and toothbrushes, Olay and Old Spice against Palmolive and Softsoap, and Dawn and Tide against Colgate's home-care lines.

P/E: 33.8Score: 72Market cap: $24.91B

Church & Dwight targets the same US household shopper with TheraBreath mouthwash and Arm & Hammer toothpaste against Colgate's oral care, and with Arm & Hammer and OxiClean against its cleaning brands.

Unilever PLCULVR

Unilever fights Colgate for the same shelf space in oral care (Closeup, Pepsodent) and personal care (Dove, Lifebuoy), above all in the emerging markets that generate a large share of Colgate's sales.

Haleon plcHLN

Haleon is the main rival in premium therapeutic oral care, where Sensodyne, Parodontax and Polident compete directly with Colgate Sensitive, Colgate Total and Colgate's denture-care products, often on pharmacist and dentist recommendation.

Nestlé S.A.NESN

Through Purina and Purina Pro Plan Veterinary Diets, Nestlé is the largest player in the pet food aisles and veterinary clinics where Colgate's Hill's Science Diet and Prescription Diet earn roughly a quarter of group sales.

Reckitt Benckiser Group plcRKT

Reckitt competes for the same home-care and hygiene budget, with Lysol, Finish and Air Wick facing Colgate's Ajax, Fabuloso, Axion and Suavitel across the US, Europe and Latin America.

Balance Sheet & Liquidity

Revenue

$21.05B

Trailing 12 months (through 6/30/2026)

Net Income

$2.04B

Trailing 12 months (through 6/30/2026)

Free Cash Flow

$3.63B

Total Equity

$54M

Total Liabilities

$15.96B

Current Ratio

1.03

Interest Coverage

12.32

Debt/EBITDA

1.99

Earnings Per Share

Revenue & Net Income

Free Cash Flow

Income Breakdown

Historical statement

Margins over time

Debt over time

How heavy the debt is

Growth grid

Growth — Revenue

Fair Value Estimation

General caseOvervalued

Fair Value

$71.83

Current Price

$94.04

Margin of Safety

-30.9%

Fair Value Range

$46.69 - $96.97

Spread across the valuation methods used, not a statistically calibrated confidence interval.

Estimation Methods

Analyst price target:$98.15
Discounted cash flow (DCF):$82.51
Earnings multiple (P/E):$54.70
Graham growth formula:$19.00
Earnings power value (EPV):$38.70
Justified P/B:$10.57
Dividend discount (Gordon):$58.74
P/FFO, funds from operations:$55.44
Mid-cycle earnings:$101.98
Revenue multiple:$35.32
Last Earnings Surprise:+1.51%

Valuation Metrics

P/E Ratio

37.17

ROE

3948.1%

P/B Ratio

317.65

P/FCF

19.43

Gross Margin

60.4%

ROIC

23.2%

Profitability Radar

Value Creation (Economic Moat)

ROIC

23.2%

WACC

7.5%

ROIC − WACC

+15.7 pp

ROIC exceeds the cost of capital — the company is creating value for shareholders.

Fundamental Analysis Criteria

Passed (13)

  • ROIC 23.2%
  • Gross margin 60.4%
  • P/FCF 19.43
  • Operating margin 14.9%
  • Positive free cash flow
  • CapEx intensity
  • Current ratio
  • Interest coverage
  • Debt/EBITDA
  • Return on tangible assets
  • ROE 631.1%
  • Earnings quality (operating cash flow / net income) 2.19
  • Share dilution -1.5%

Failed (12)

  • EPS shows upward trend
  • EPS CAGR -1.08%
  • Price CAGR 3.55%
  • P/B ratio 317.65
  • Debt/equity ratio
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • Revenue growth 5Y 4.3%
  • Earnings surprise, average 0.4%
  • Net margin trend 9.7% vs 14.5%
  • Piotroski F-Score 4/9

Unavailable (2)

  • Dividend payout –
  • PEG ratio (needs P/E > 0 and growth > 0)

Piotroski F-Score

4/9

Mixed signals: some areas need attention

ROA > 0
Operating cash flow > 0
ΔROA > 0
Cash flow > net income
Leverage ↓
Current ratio ↑
No dilution
Gross margin ↑
Asset turnover ↑

Earnings Quality

2.19

High quality: earnings backed by cash

Share Dilution

-1.5%

Buying back shares. Shareholder friendly

Institutional Holdings

Governance

Executive Team

NameTitleAge
Mr. Noel R. WallaceChairman, CEO & President61
Mr. Stanley J. Sutula IIIChief Financial Officer59
Mr. Panagiotis TsourapasCOO of Global Customer Dev., Europe Middle East Africa, Asia Pacific & Global Skin Health60
Mr. Shane GrantChief Operating Officer of Americas50
Mr. Stephan HabifChief Technology Officer-
Mr. David FosterChief Information Officer-
Ms. Betsy FishboneEVP, Chief Legal Officer & Secretary-
Mr. Eutychus KaruruExecutive Vice President of Internal Audit & Compliance-
Mr. Dana BoldenChief Communications Officer57
Mr. Ram RaghavanChief Marketing Officer52

Audit Risk

3

Board Risk

5

Compensation Risk

4

Shareholder Rights Risk

2

Documents

  • Annual Report (10-K)

    A yearly overview of the business, its financial results, and the risks it faces.

    Filed on 2026-02-23

    View document
  • Quarterly Report (10-Q)

    A snapshot of financial performance for the most recent three-month period.

    Filed on 2026-07-31

    View document
  • Current Report (8-K)

    An announcement of a major event, such as a leadership change or big news.

    Filed on 2026-07-31

    View document

via SEC EDGAR

Income History

via SEC EDGAR

Part 2 · The price and its context

This part shows how the price has behaved, not whether the company is worth owning. Inside: technical analysis, potential, historical drawdowns, gamma exposure.

Market Reaction Profile

How much CL moves, measured on its daily prices.

VolatilityLow

More volatile than 13% of the tracked stocks (90-day volatility).

Volatility 30d
24.1%
Volatility 90d
22.4%
Beta vs S&P 500 (1y)
-0.16Correlation -0.09
Max drawdown (12m)
-17.5%
ATR (14d, % of price)
2.04%

Earnings reactions

How CL moved around its past quarterly results.

Next earnings release

Oct 30, 2026 · In 6 days · Before the open

EPS estimate: 0.93Revenue estimate: $5.3B

What usually happens

  • Over the last 12 releases the stock moved a median of 1.9% the next day, up or down.
  • Next-day moves: up 7, down 5 (out of 12).

Release history

DateWhen EPS est.EPS actualSurprise Gap 1 day5 days
Jul 31, 2026Before the open0.980.99+1.5% -0.8% -0.3% +1.5%
May 1, 2026Before the open0.970.97-0.3% +3.3% +2.2% +2.3%
Jan 30, 2026Before the open0.940.95+1.1% +4.1% +5.9% +11.3%
Oct 31, 2025Before the open0.920.91-0.5% -1.3% +0.7% +1.0%
Aug 1, 2025Before the openn/an/an/a+0.2% -0.4% +1.0%
Apr 25, 2025Before the openn/an/an/a+3.0% +1.3% -2.2%
Jan 31, 2025Before the openn/an/an/a-6.0% -4.6% -5.7%
Jul 26, 2024Before the openn/an/an/a+2.6% +3.0% +4.6%
Apr 26, 2024Before the openn/an/an/a+1.9% +1.9% +4.1%
Jan 26, 2024Before the openn/an/an/a+0.4% +2.0% +6.0%
Oct 27, 2023Before the openn/an/an/a+0.3% -1.8% +2.4%
Jul 28, 2023Before the openn/an/an/a-2.5% -1.9% -0.7%

Release dates from SEC 8-K filings.

Updated 10/24/2026

Historical statistics for educational purposes only. They are not forecasts and not investment advice.

Price reaction to the news

Latest news on CL and what the price did next.

No positive or negative news on CL has been archived yet.

Return of the stock minus return of SPY over the same days. A news item close to a price move did not necessarily cause it. Historical data for educational purposes only, not investment advice.

Latest News

Recent headlines for CL.

No recent news for CL.